JYPC(SZ:002198) YOUNG财经 漾财经·2025-11-24 10:30Core Viewpoint - The article discusses the penalties imposed on Jiaying Pharmaceutical for violations related to related party transactions and information disclosure, resulting in a total fine of 4.9 million yuan and various regulatory measures [2][3][4]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its chairman Li Neng, along with three other key personnel, received a total fine of 4.9 million yuan from the Guangdong Securities Regulatory Bureau for failing to disclose related party transactions and not following the necessary review procedures [2][4]. - The company also received a warning and a public reprimand from the Shenzhen Stock Exchange, highlighting the severity of the violations [2][4]. Violations Details - The violations involved non-operational fund transfers between Jiaying Pharmaceutical's subsidiary and a related party, with total amounts reaching 220 million yuan, which constituted 28.83% of the company's latest audited net assets [3][4]. - The highest daily balance of funds transferred to the related party was 89.96 million yuan, accounting for 11.79% of the company's net assets [3]. Penalties Breakdown - The penalties included a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, while chairman Li Neng was fined 1.6 million yuan, and other executives received fines ranging from 800,000 to 1 million yuan [4]. - The company has stated that it will enhance compliance awareness and ensure accurate information disclosure moving forward [4]. Previous Violations - This is not the first time Jiaying Pharmaceutical has faced penalties for information disclosure issues, as it previously received a warning in 2021 for failing to timely disclose significant matters [5].